These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 22712629)

  • 21. Dextromethorphan/quinidine for the treatment of pseudobulbar affect.
    Patatanian E; Casselman J
    Consult Pharm; 2014 Apr; 29(4):264-9. PubMed ID: 24704895
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Steady-state pharmacokinetics of galantamine are not affected by addition of memantine in healthy subjects.
    Yao C; Raoufinia A; Gold M; Nye JS; Ramael S; Padmanabhan M; Walschap Y; Verhaeghe T; Zhao Q
    J Clin Pharmacol; 2005 May; 45(5):519-28. PubMed ID: 15831775
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dextromethorphan: enhancing its systemic availability by way of low-dose quinidine-mediated inhibition of cytochrome P4502D6.
    Zhang Y; Britto MR; Valderhaug KL; Wedlund PJ; Smith RA
    Clin Pharmacol Ther; 1992 Jun; 51(6):647-55. PubMed ID: 1611804
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Physiologically based modelling of inhibition of metabolism and assessment of the relative potency of drug and metabolite: dextromethorphan vs. dextrorphan using quinidine inhibition.
    Moghadamnia AA; Rostami-Hodjegan A; Abdul-Manap R; Wright CE; Morice AH; Tucker GT
    Br J Clin Pharmacol; 2003 Jul; 56(1):57-67. PubMed ID: 12848776
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety, Tolerability, and Effectiveness of Dextromethorphan/Quinidine for Pseudobulbar Affect Among Study Participants With Traumatic Brain Injury: Results From the PRISM-II Open Label Study.
    Hammond FM; Sauve W; Ledon F; Davis C; Formella AE
    PM R; 2018 Oct; 10(10):993-1003. PubMed ID: 29477412
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low doses of dextromethorphan have a beneficial effect in the treatment of neuropathic pain.
    Morel V; Pickering G; Etienne M; Dupuis A; Privat AM; Chalus M; Eschalier A; Daulhac L
    Fundam Clin Pharmacol; 2014 Dec; 28(6):671-80. PubMed ID: 24702319
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions.
    Pattee GL; Wymer JP; Lomen-Hoerth C; Appel SH; Formella AE; Pope LE
    Curr Med Res Opin; 2014 Nov; 30(11):2255-65. PubMed ID: 25062507
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclinical toxicity study of intrathecal administration of the pain relievers dextrorphan, dextromethorphan, and memantine in the sheep model.
    Hassenbusch SJ; Satterfield WC; Gradert TL; Binhazim AW; Ahad G; Mokhtarzadeh M; Schapiro SJ; Payne R
    Neuromodulation; 1999 Nov; 2(4):230-40. PubMed ID: 22151256
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dextromethorphan/Quinidine in Migraine Prophylaxis: An Open-label Observational Clinical Study.
    Berkovich RR; Sokolov AY; Togasaki DM; Yakupova AA; Cesar PH; Sahai-Srivastava S
    Clin Neuropharmacol; 2018; 41(2):64-69. PubMed ID: 29474194
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
    Walzer M; Bekersky I; Blum RA; Tolbert D
    Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dextromethorphan/quinidine: AVP 923, dextromethorphan/cytochrome P450-2D6 inhibitor, quinidine/dextromethorphan.
    Drugs R D; 2005; 6(3):174-7. PubMed ID: 15869321
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial.
    Brooks BR; Thisted RA; Appel SH; Bradley WG; Olney RK; Berg JE; Pope LE; Smith RA;
    Neurology; 2004 Oct; 63(8):1364-70. PubMed ID: 15505150
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of dextromethorphan/quinidine on pentylenetetrazole- induced clonic and tonic seizure thresholds in mice.
    Jamali H; Heydari A
    Neurosci Lett; 2020 Jun; 729():134988. PubMed ID: 32325102
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of Dextromethorphan/Quinidine for Patients With Psychosis-Related Aggression: A Retrospective Case Series.
    Chen Q; Calcagno HE; Shad M
    Prim Care Companion CNS Disord; 2018 Jun; 20(3):. PubMed ID: 29985567
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dextromethorphan/quinidine: a review of its use in adults with pseudobulbar affect.
    Yang LP; Deeks ED
    Drugs; 2015 Jan; 75(1):83-90. PubMed ID: 25420446
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dextromethorphan/quinidine pharmacotherapy in patients with treatment resistant depression: A proof of concept clinical trial.
    Murrough JW; Wade E; Sayed S; Ahle G; Kiraly DD; Welch A; Collins KA; Soleimani L; Iosifescu DV; Charney DS
    J Affect Disord; 2017 Aug; 218():277-283. PubMed ID: 28478356
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial.
    Cummings JL; Lyketsos CG; Peskind ER; Porsteinsson AP; Mintzer JE; Scharre DW; De La Gandara JE; Agronin M; Davis CS; Nguyen U; Shin P; Tariot PN; Siffert J
    JAMA; 2015 Sep 22-29; 314(12):1242-54. PubMed ID: 26393847
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of concomitant quinidine administration on dextromethorphan disposition in rats.
    Marier JF; Pope LE; Yakatan GJ; Berg JE; Stiles M; Vachon P
    J Vet Pharmacol Ther; 2004 Apr; 27(2):111-4. PubMed ID: 15096109
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study.
    Ermer J; Corcoran M; Martin P
    Drugs R D; 2015 Jun; 15(2):175-85. PubMed ID: 25862215
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury.
    Hammond FM; Alexander DN; Cutler AJ; D'Amico S; Doody RS; Sauve W; Zorowitz RD; Davis CS; Shin P; Ledon F; Yonan C; Formella AE; Siffert J
    BMC Neurol; 2016 Jun; 16():89. PubMed ID: 27276999
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.